This article focuses on advances in the understanding of the pathogenesis and treatment of diabetic cardiomyopathy. Patients with diabetes are at an elevated risk for heart failure, and comorbid heart failure confers an increased risk of morbidity and mortality. Diabetic cardiomyopathy and to apply proven lifesaving therapies in all heart failure patients, including those with diabetes, in the absence of contraindications or intolerance.
Ahmanson-UCLA Cardiomyopathy Center, UCLA Division of Cardiology, David Geffen School of Medicine at UCLA, 10833 Leconte Avenue, Room BH407, Los Angeles, CA 90095, USA. gfonaarow@mednet.uca.edu
